Navigation Links
Pharsight Strengthens Senior Management Team
Date:4/29/2008

John Murphy Appointed as New Senior Vice President of Consulting Services

MOUNTAIN VIEW, Calif., April 29 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that it has expanded its management team by appointing John E. Murphy, DrPH, as Senior Vice President of Consulting Services. In this role, Dr. Murphy will lead the Company's two global scientific consulting units focused on the strategic application of model-based drug development and regulatory-compliant PK/PD analysis and reporting services.

Dr. Murphy brings more than 25 years of pharmaceutical industry services, software and strategic management experience to the Pharsight executive team. Prior to joining Pharsight, Dr. Murphy was Principal and Executive Advisor at Booz Allen Hamilton, Inc., where he worked with leading pharmaceutical, biotechnology and high-technology companies developing strategies and implementing solutions to improve R&D productivity. Before this, Dr. Murphy served as Vice President and Chief Information Officer at CuraGen Corporation, a publicly traded biopharmaceutical company. While at CuraGen, he directed business development and information technology services for the company and its pharmaceutical partners and clinical trials network.

"Pharsight's modeling and simulation methodology and accompanying software solutions are on the leading edge of traditional drug development processes and are continuing to gain mindshare in the industry," said Dr. Murphy. "I look forward to working with the senior management team and its world-class scientific consulting groups to further strengthen Pharsight's service offerings that address the growing needs of pharmaceutical and biotechnology companies to more efficiently develop their pipeline of products."

"John's extensive pharmaceutical industry background and experience with companies focused on enabling services and technology for pharmaceutical development will allow him to contribute meaningfully to Pharsight's future growth," said Shawn O'Connor, president, chief executive officer and chairman of Pharsight. "We believe John's leadership of both Pharsight's scientific consulting units, Strategic Consulting Services (SCS) and Reporting and Analysis Services (RAS), will be particularly valuable as we execute on our plans to expand these teams' capabilities, leverage our industry-leading software, and further enhance the services that we provide to our clients to improve drug development productivity and decision-making. We are very excited to welcome John to Pharsight."

Prior to joining CuraGen, Dr. Murphy was founder and chief executive officer at Just Medicine Incorporated, a developer of regulatory-compliant clinical software for the management of real-time data collection and analysis. He was instrumental in the eventual sale of Just Medicine Incorporated and its clinical network to a joint venture formed by two leading global pharmaceutical companies. Dr. Murphy has also held a number of other senior leadership roles in medical device companies, life sciences software technology companies and healthcare delivery organizations, including Predict Incorporated, Community Health Computing and Mercy Hospital in Watertown, New York.

Before Dr. Murphy began his career in the pharmaceutical industry, he held senior health care policy management and research positions at the Sloan Commission on Government and Higher Education in Washington, DC, at the Massachusetts Institute of Technology, and with the Health Planning Council for Greater Boston. He has lectured on numerous life sciences technology and pharmaceutical research topics, and has authored journal articles in publications such as Health Care Informatics and the New England Journal of Medicine. He is also the author of 17 patents, including 12 approved or pending patents on clinical software and data mining techniques.

Dr. Murphy earned his masters and doctor of Public Health degrees from Columbia University, and throughout his career has completed various software training certifications as well as executive-level programs in healthcare finance and health information systems management.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this document are trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pharsight Announces Fiscal Fourth Quarter 2008 and Year End Earnings Release Date and Conference Call
2. Pharsight Signs New Diabetes Meta-Database Customer
3. Pharsight to Present at eClinical Forum
4. Pharsight to Host Webinar on Hepatitis C Virus (HCV) and HIV Drug-Disease Modeling
5. FDA and Pharsight Continue to Collaborate Under CRADA
6. Pharsight to Present at DIA Cardiac Safety Conference on December 4, 2007
7. Pharsight Achieves $7.3 Million in Quarterly Revenue
8. Pharsight Expands Global Consulting Services Teams
9. Pharsight to Host European Software Conference
10. Pharsight Files Application for Nasdaq Capital Market Listing
11. Life Brokerage Partners Strengthens Premium Finance Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... La. (PRWEB) , ... February 18, 2017 , ... ... released today provides the latest information and contact points to easily connect elderly ... home care, assisted living, and elder-care funding. It also conveys material on this ...
(Date:2/17/2017)... Murfreesboro, TN (PRWEB) , ... February 17, 2017 ... ... EHR mobility has not kept pace. Enovate Medical has introduced an innovative workstation ... 20 years of supporting nurses, the Encore Mobile EHR Workstation offers a lightweight, ...
(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... software tools that allow for the electronic prescribing of controlled and non-controlled substances ... , Ninety percent of pharmacies in the United States now accept electronic prescriptions, ...
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... ... ... to Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. ... , What are the critical reimbursement questions manufacturers should be asking ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 ... manufacturers distinguish between corrective action (CA) and preventive action (PA)? , The methods ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... TOWN, South Africa , Feb. 20, 2017 /PRNewswire/ ... of illness and non-communicable diseases (NCDs) across sub-Saharan Africa, ... prescription drugs. The growing incidence of more Western lifestyle ... respiratory disease, in addition to infectious and parasitic illness, ... with a business opportunity of $40.8 billion ...
(Date:2/20/2017)... SAN FRANCISCO , February 20, 2017 /PRNewswire/ ... (CSF) management market  is anticipated to reach USD ... report by Grand View Research, Inc. Constant evaluation ... hydrocephalus management is expected to drive growth in ... the investment for development of novel and improved ...
(Date:2/20/2017)... 20, 2017 Acute, Chronic and Prophylaxis GVHD ... at a CAGR of 7% from 2016-2021 and CAGR of 3% from ... from 2016 to 2027. The market is estimated at $0.36bn in 2016, ... ... discover how you can exploit the future business opportunities emerging in this ...
Breaking Medicine Technology: